# Radiotherapy Plus Hormone Therapy in Biochemically-relapsing Prostate Cancer Patients Following Surgery

> **NCT01780220** · PHASE1,PHASE2 · COMPLETED · sponsor: **UNICANCER** · enrollment: 47 (actual)

## Conditions studied

- Biochemically-relapsing Prostate Adenocarcinoma Following Radical Prostatectomy

## Interventions

- **DRUG:** Abiraterone

## Key facts

- **NCT ID:** NCT01780220
- **Lead sponsor:** UNICANCER
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-12
- **Primary completion:** 2022-01-07
- **Final completion:** 2022-01-07
- **Target enrollment:** 47 (ACTUAL)
- **Last updated:** 2022-05-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01780220

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01780220, "Radiotherapy Plus Hormone Therapy in Biochemically-relapsing Prostate Cancer Patients Following Surgery". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT01780220. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*